In an exploratory secondary analysis of the phase 2 ENVISION trial in adults with IgA nephropathy, symptomatic COVID-19 was 33.3% with sibeprenlimab vs 44.7% with placebo; in 72 substudy participants, antibody responses to vaccine and infection appeared preserved.
Secondary analysisn = 155
McCafferty et al. Humoral Response to COVID-19 Vaccines and Infection during Sibeprenlimab Treatment of IgA Nephropathy: Data from the ENVISION Trial